This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhong, C. Articles by Roy-Burman, P. Search for Related Content PubMed PubMed Citation Articles by Zhong, C. Articles by Roy-Burman, P.

Cooperation between FGF8b Overexpression and PTEN Deficiency in Prostate Tumorigenesis

Departments of ¹ Pathology and ² Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, California; and ³ Department of Pathology, The University of Iowa, Iowa City, Iowa

Requests for reprints: Pradip Roy-Burman, Department of Pathology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue, Los Angeles, CA 90033. Phone: 323-442-1184; Fax: 323-442-3049; E-mail: royburma{at}usc.edu.

Two commonly occurring genetic aberrations of human prostate cancer [i.e., overexpression of a mitogenic polypeptide (fibroblast growth factor 8, isoform b or FGF8b) and loss of function of PTEN tumor suppressor] were recapitulated into a new combinatorial mouse model. This model harboring the Fgf8b transgene and haploinsufficiency in Pten, both in a prostate epithelium–specific manner, yielded prostatic adenocarcinoma with readily detectable lymph node metastases, whereas single models with each of the defects were shown earlier to progress generally only up to prostatic intraepithelial neoplasia (PIN). In addition to late age-related development of typical adenocarcinoma, the model also displayed a low incidence of mucinous adenocarcinoma, a rare variant type of human prostatic adenocarcinoma. The cooperation between FGF8b activation and PTEN deficiency must be linked to acquisition of additional genetic alterations for the progression of the lesions to primary adenocarcinoma. Here, we identified loss of heterozygosity at the Pten gene leading to bialleic loss, as a necessary secondary event, indicating that a complete loss of PTEN function is required in the development of invasive cancer in the model. Analyses of expression of downstream mediators phospho-AKT (p-AKT) and p27^KIP1, in various types of lesions, however, revealed a complex picture. Although PIN lesions displayed relatively strong expression of p-AKT and p27^KIP1, there was a notable heterogeneity with variable decrease in their immunostaining in adenocarcinomas. Together, the results further underscore the notion that besides activation of AKT by loss of PTEN function, other PTEN-regulated pathways must be operative for progression of lesions from PIN to adenocarcinoma. (Cancer Res 2006; 66(4): 2188-94)

This article has been cited by other articles:

				A. Amsterdam, K. Lai, A. Z. Komisarczuk, T. S. Becker, R. T. Bronson, N. Hopkins, and J. A. Lees Zebrafish Hagoromo Mutants Up-Regulate fgf8 Postembryonically and Develop Neuroblastoma Mol. Cancer Res., June 1, 2009; 7(6): 841 - 850. [Abstract] [Full Text] [PDF]

				O. C. Rodriguez, E. W. Lai, S. Vissapragada, C. Cromelin, M. Avetian, P. Salinas, H. Ramos, B. Kallakury, M. Casimiro, M. P. Lisanti, et al. A Reduction in Pten Tumor Suppressor Activity Promotes ErbB-2-Induced Mouse Prostate Adenocarcinoma Formation through the Activation of Signaling Cascades Downstream of PDK1 Am. J. Pathol., June 1, 2009; 174(6): 2051 - 2060. [Abstract] [Full Text] [PDF]

				J. Blando, M. Portis, F. Benavides, A. Alexander, G. Mills, B. Dave, C. J. Conti, J. Kim, and C. L. Walker PTEN Deficiency Is Fully Penetrant for Prostate Adenocarcinoma in C57BL/6 Mice via mTOR-Dependent Growth Am. J. Pathol., May 1, 2009; 174(5): 1869 - 1879. [Abstract] [Full Text] [PDF]

				S. Han, J. D. Ritzenthaler, Y. Zheng, and J. Roman PPAR{beta}/{delta} agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-{kappa}B signals Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1238 - L1249. [Abstract] [Full Text] [PDF]

				S. Yang, L. K. Pham, C.-P. Liao, B. Frenkel, A. H. Reddi, and P. Roy-Burman A Novel Bone Morphogenetic Protein Signaling in Heterotypic Cell Interactions in Prostate Cancer Cancer Res., January 1, 2008; 68(1): 198 - 205. [Abstract] [Full Text] [PDF]

				C.-P. Liao, C. Zhong, G. Saribekyan, J. Bading, R. Park, P. S. Conti, R. Moats, A. Berns, W. Shi, Z. Zhou, et al. Mouse Models of Prostate Adenocarcinoma with the Capacity to Monitor Spontaneous Carcinogenesis by Bioluminescence or Fluorescence Cancer Res., August 1, 2007; 67(15): 7525 - 7533. [Abstract] [Full Text] [PDF]

				R. Bedolla, T. J. Prihoda, J. I. Kreisberg, S. N. Malik, N. K. Krishnegowda, D. A. Troyer, and P. M. Ghosh Determining Risk of Biochemical Recurrence in Prostate Cancer by Immunohistochemical Detection of PTEN Expression and Akt Activation Clin. Cancer Res., July 1, 2007; 13(13): 3860 - 3867. [Abstract] [Full Text] [PDF]

				Q. Wei, L. Clarke, D. K. Scheidenhelm, B. Qian, A. Tong, N. Sabha, Z. Karim, N. A. Bock, R. Reti, R. Swoboda, et al. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res., August 1, 2006; 66(15): 7429 - 7437. [Abstract] [Full Text] [PDF]